Arkolith/Insider Trading/MBX/Form 4

Hawryluk P. Kent

President & CEO, DirectorMBX Biosciences, Inc. (MBX) · full profile →Form 4 · filed Sep 17, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
2 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)284K——481K
Sep 16, 2024Conversion(C)116K——398K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 16, 2024Conversion(C)2.0M——0
Sep 16, 2024Conversion(C)346K——0
Sep 16, 2024Conversion(C)971K——0
Sep 16, 2024Conversion(C)77K——0
Sep 16, 2024Conversion(C)1.4M——0

Transaction Codes

C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-107527) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML